Dosimetric Reporting of CT based Intraluminal Brachytherapy in Carcinoma Oesophagus: A Single Institutional Study

  • Unique Paper ID: 167761
  • Volume: 11
  • Issue: 4
  • PageNo: 292-297
  • Abstract:
  • Background: Intraluminal brachytherapy results in, high therapeutic ratio and remains an important part of the multimodality treatment of oesophageal cancer. But there is a lack of established dosimetric evaluation and guidance for the same. The aim of this study is to evaluate and report the dosimetric characteristics in ILBT patients. Materials and Methods: From January 2014 to December 2021, data of oesophageal cancer patients treated with radical external beam radiotherapy followed by ILBT was retrospectively collected and these patient’s dosimetric parameters were also retrieved from planning systems and documents. The volume of target, dose to target and dose to lungs, heart and spinal cord was recorded. Results: Twenty patients were taken for this study. The mean treatment length was 5.65+2.09 cm. Mean HRCTV V100 was 21.9% and HRCTV V200 was 7.9% and this corresponds to 75% and 25% of the target volume, respectively. The mean D2cc received by the B/L lung, heart and spinal cord was 63%, 61% and 15% of the prescription dose respectively. The median disease free survival observed was 13.05+9.88 months. Conclusion: The treatment regimens and techniques used in ILBT are vast and varied. Our study emphasises on consistent, safe treatment policies for the use of CT based HDR ILBT in oesophageal cancer.

Related Articles